|
2019 Conference Publication Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS)Lechner-Scott, Jeannette, Maltby, Vicky, Lyndon, Amanda, Monif, Mastura, Kilpatrick, Trevor, Butzkueven, Helmut, Taylor, Bruce, McCombe, Pamela, Hodgkinson, Suzanne, Fabis-Pedrini, Marzena, Kermode, Allan, Barnett, Michael and Kalincik, Tomas (2019). Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS). Annual Scientific Meeting of the Australian and New Zealand Association of Neurologists (ANZAN), Sydney, Australia, May 21-24, 2019. London, United Kingdom: B M J Group. doi: 10.1136/jnnp-2019-anzan.119 |
|
2019 Conference Publication Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)McCombe, P., Comi, G., Arnold, D. L., Boyko, A. N., Hartung, H-P., Havrdova, E. K., Inshasi, J. S., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S. and Van Wijmeersch, B. (2019). Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study). Congress of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Sydney, NSW Australia, 2018. London, United Kingdom: Sage. |
|
2019 Conference Publication Alemtuzumab maintains efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 9 years in RRMS patients: CARE-MS I follow-up (TOPAZ study)Montalban, X., Arnold, D. L., Boyko, A. N., Comi, G., Hartung, H.-P., Havrdova, E. K., Inshasi, J. S., McCombe, P., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Scott, T. F., Vieira Alves Leon, S., Chung, L., Daizadeh, N., Afsar, S. and Selmaj, K. W. (2019). Alemtuzumab maintains efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 9 years in RRMS patients: CARE-MS I follow-up (TOPAZ study). 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications. |
|
2019 Conference Publication Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Clinical Study and Postmarketing DataMcCombe, P., Vukusic, S., Coyle, P. K., Jurgensen, S., Truffinet, P., Benamor, M., Poole, E., Chavin, J. and Chambers, C. (2019). Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Clinical Study and Postmarketing Data. Congress of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Sydney, NSW Australia, 2018. London, United Kingdom: Sage. |
|
2019 Conference Publication Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 yearsCelius, E. G., Achiron, A., Compston, D. A. S., Derwenskus, J., Devonshire, V., Hellwig, K., Hutton, G. J., McCombe, P., Moore, M., Oh, J., Simm, R. F., Sousa, L., Vincent, S. G., Chung, L., Daizadeh, N., Mitchell, C. and Rog, D. (2019). Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 years. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications. |
|
2018 Conference Publication Clinical and therapeutic predictors of relapse and disability outcomes in neuromyelitis optica spectrum disorderKunchok, A., Malpas, C., Horakova, D., Havrdova, E., Alroughani, R., Terzi, M., Yamout, B., Karabudak, R., Boz, C., Ozakbas, S., Olascoagam, J., Simon, M., Granellau, F., McCombe, P., Csepanym, T., Bergamaschi, R., Fragoso, Y., Al-Harbin, T., Turkoglu, R., Lechner-Scott, J., Laureys, G., Pucci, E., Sola, P., Ferraro, D., Altintas, A., Grand'Maison, F., Izquierdo, G., Eichau, S., Lugaresi, A. ... Kalincik, T. (2018). Clinical and therapeutic predictors of relapse and disability outcomes in neuromyelitis optica spectrum disorder. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD. |
|
2018 Conference Publication Disability outcomes in patients with early cerebellar symptoms in multiple sclerosisLe, M. V. H., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Ozakbas, S., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Alroughani, R., Bergamaschi, R., Sola, P., Grammond, P., Grand'Maison, F., Terzi, M., Boz, C., Hupperts, R., Butzkueven, H., Van der Walt, A., Pucci, E., Granella, F., Van Pesch, V., Soysa, A., Yamout, B., Lechner-Scott, J. ... Kalincik, T. (2018). Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD. |
|
2018 Conference Publication Alemtuzumab improves clinical and MRI disease activity outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ study)Comi, G., Arnold, D. L., Boyko, A. N., Hartung, H. -P., Havrdova, E. K., Inshasi, J. S., McCombe, P., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S., Nakamura, K. and Van Wijmeersch, B. (2018). Alemtuzumab improves clinical and MRI disease activity outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ study). 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD. |
|
2018 Conference Publication Determinants of MS re-activation after discontinuing therapiesHusin, H., Wallace, J., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. Kubala, Izquierdo, G., Eichau, S., Prat, A., Girard, M., Duquette, P., Trojano, M., Grammond, P., Lugaresi, A., Onofrj, M., Ozakbas, S., Butzkueven, H., Sola, P., Ferraro, D., Alroughani, R., Grand'Maison, F., Terzi, M., Lechner-Scott, J., Boz, C., Hupperts, R., Shaygannejad, V., Bergamaschi, R., Pucci, E., Van Pesch, V. ... Kalincik, T. (2018). Determinants of MS re-activation after discontinuing therapies. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD. |
|
2018 Conference Publication Early clinical predictors of severe MSMalpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Bergamaschi, R., Sola, P., Ferraro, D., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand'Maison, F., Ozakbas, S., Van Pesch, V., Granella, F., Hupperts, R., Pucci, E., Boz, C., Iuliano, G., Sidhom, Y., Gouider, R., Spitaleri, D., Butzkueven, H., Soysal, A., Petersen, T., Verheul, F. ... Kalincik, T. (2018). Early clinical predictors of severe MS. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD. |
|
2018 Conference Publication Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registrySpelman, T., Harvrdova, E. K., Horakova, D., Izquierdo, G., Kalincik, T., Lugaresi, A., Onofrj, M., Duquette, P., Girard, M., Prat, A., Grammond, P., Grand'Maison, F., Granella, F., Lechner-Scott, J., Sola, P., Ferrero, D., Sa, M. J., Terzi, M., Ozakbas, S., Van Pesch, V., Van Wijmeersch, B., Boz, C., Karabudak, R., Cartechini, E., McCombe, P. and Butzkueven, H. (2018). Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD. |
|
2018 Conference Publication Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)Steingo, Brian, Oreja-Guevara, Celia, Alroughani, Raed, Brassat, David, Boyko, Alexey N., McCombe, Pamela, Van Wijmeersch, Bart, Margolin, David H., Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Vermersch, Patrick (2018). Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study). AAN 70th Annual Meeting, Los Angeles, CA United States, 21-27 April 2018. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.90.15_supplement.p6.366 |
|
2018 Conference Publication Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase RegistryKister, Ilya, Bacon, Tamar, Shaygannejad, Vahid, Havrdova, Eva, Alroughani, Raed, Terzi, Murat, Altintas, Ayse, Hor, Jyh Yung, Al-Harbi, Talal, Boz, Cavit, Bergamaschi, Roberto, Ozakbas, Serkan, Ferraro, Diana, Fragoso, Yara, Laureys, Guy, Soysal, Aysun, Majdinassab, Nastaran, Onofrj, Marco, Pucci, Eugenio, Vucic, Ostoja (Steve), Slee, Mark, Lechner-Scott, Jeannette, Rojas, Juan Ignacio, Burgos, Marcos, Castillo Trivino, Tamara, Reid, Allyson, Rimler, Zoe, McCombe, Pamela, Granella, Franco ... Butzkueven, Helmut (2018). Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry. 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los Angeles Ca, Apr 21-27, 2018. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2018 Conference Publication Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study)Vermersch, Patrick, Coles, Alasdair J., Boyko, Alexey N., De Seze, Jérôme, Hartung, Hans-Peter, Havrdova, Eva, Inshasi, Jihad Said, McCombe, Pamela, Montalban, Xavier, Pozzilli, Carlo, Selmaj, Krzysztof W., Margolin, David H., Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Van Wijmeersch, Bart (2018). Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study). AAN 70th Annual Meeting, Los Angeles, CA United States, 21-27 April 2018. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.90.15_supplement.p6.376 |
|
2018 Conference Publication Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study)Van Wijmeersch, B., Vermersch, P., Boyko, A., de Seze, J., Hartung, H. -P., Havrdova, E. Kubala, Inshasi, J. Said, McCombe, P., Montalban, X., Pozzili, C., Melanson, M., Daizadeh, N., Rodriguez, C. and Selmaj, K. (2018). Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study). 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, 16-19 June 2018. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. |
|
2018 Conference Publication Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study)Vermersch, Patrick, Coles, Alasdair J., Boyko, Alexey N., De Seze, Jerome, Hartung, Hans-Peter, Havrdova, Eva, Inshasi, Jihad Said, McCombe, Pamela, Montalban, Xavier, Pozzilli, Carlo, Selmaj, Krzysztof W., Margolin, David H., Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Van Wijmeersch, Bart (2018). Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study). 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los Angeles, CA, United States, Apr 21-27, 2018. Philadelphia, PA, United States: Lippincott Williams & Wilkins. |
|
2018 Conference Publication Durable improvements in clinical outcomes with alemtuzumab in patients with active relapsing-remitting multiple sclerosis in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study)Inshasi, Jihad Said, Boyko, Alexey N., De Seze, Jerome, Hartung, Hans-Peter, Havrdova, Eva, McCombe, Pamela, Montalban, Xavier, Pozzilli, Carlo, Vermersch, Patrick and Margolin, David H. (2018). Durable improvements in clinical outcomes with alemtuzumab in patients with active relapsing-remitting multiple sclerosis in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study). 3rd Congress of Middle East North Africa Committee for Research and Treatment in Multiple Sclerosis (MENACTRIMS), Dubai, UAE, 24-25 November 2017 . London, United Kingdom : Sage Publications. |
|
2018 Conference Publication Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)Steingo, Brian, Oreja-Guevara, Celia, Alroughani, Raed, Brassat, David, Boyko, Alexey N., McCombe, Pamela, Van Wijmeersch, Bart, Margolin, David H., Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Vermersch, Patrick (2018). Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study). 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los Angeles, CA, United States, Apr 21-27, 2018. Philadelphia, PA, United States: Lippincott Williams & Wilkins. |
|
2018 Conference Publication Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study)McCombe, Pamela, Boyko, Alexey N., DeSeze, Jerome, Hartung, Hans-Peter, Havrdova, Eva, Inshasi, Jihad Said, Montalban, Xavier, Pozzilli, Carlo, Selmaj, Krzysztof W., Vermersch, Patrick, Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Van Wijmeersch, Bart (2018). Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study). Annual Scientific Meeting of the Australian-and-New Zealand-Association-of-Neurologists (ANZAN), Darwin Australia, May 29 - June 1 2018. London, United Kingdom: B M J Group. doi: 10.1136/jnnp-2018-ANZAN.43 |
|
2017 Conference Publication Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CARE-MS I)Singer, Barry, Coles, Alasdair J., Boyko, Alexey N., Cohen, Jeffrey A., De Seze, Jérôme, Fox, Edward J., Havrdova, Eva, Hartung, Hans-Peter, Inshasi, Jihad Said, McCombe, Pamela, Selmaj, Krzysztof W., Vermersch, Patrick, Van Wijmeersch, Bart, Margolin, David H., Thangavelu, Karthinathan, Rodriguez, Claudio and Montalban, Xavier (2017). Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CARE-MS I). AAN 69th Annual Meeting, Boston, MA United States, 22-28 April 2017. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.88.16_supplement.s24.005 |
